Loading
ExpreS2ion Biotechnologies makes ES2B-C001, a vaccine that trains the immune system to recognise HER2, a protein found on some breast and other cancers. It is in a first trial in people with HER2-expressing breast cancer that has spread.
ExpreS2ion Biotechnologies is a clinical-stage company listed on the Nasdaq First North Growth Market in Sweden, with research and development in Hørsholm, Denmark, and a holding company address in Helsingborg, Sweden. It develops immunotherapies using its proprietary ExpreS2 protein expression system. Its lead programme ES2B-C001 is an active immunotherapy for HER2-expressing cancers that combines HER2 antigens with a virus-like particle delivery system and is designed to target all four extracellular domains of the HER2 receptor; a first-in-human phase 1 trial assesses safety with or without an adjuvant in patients with HER2-expressing metastatic breast cancer. Its first registered cancer trial, NCT06746688, was posted on ClinicalTrials.gov in December 2024.
Shares Off-the-shelf cancer vaccines, HER2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/